arrow
M

Martine L.M. Lamfers

Erasmus University Rotterdam
H指数:38
被引数:4,144

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A COMPREHENSIVE DRUG-DISCOVERY AND CLINICAL TRIAL PLATFORM FOR GLIOBLASTOMA PATIENTS. REDIRECCT: REPURPOSING DRUGS IN RESEARCH AND CANCER CLINICAL TRIALS.

胶质母细胞瘤患者的全面药物发现和临床试验平台。REDIRECCT:在研究和癌症临床试验中重新利用药物。

2025-10-010
OA
REPURPOSING DRUGS IN RESEARCH AND CANCER CLINICAL TRIALS (REDIRECCT); PHASE 0 PITAVASTATIN IN GLIOBLASTOMA PATIENTS.

药物重定位在研究和癌症临床试验中的应用(REDIRECCT);用于胶质母细胞瘤患者的Phase 0匹伐他汀。

2025-10-010
OAAI
Optimized culturing yields high success rates and preserves molecular heterogeneity, enabling personalized screening for high-grade gliomas

优化培养方法可提高成功率并保持分子异质性,从而实现针对高级别胶质瘤的个性化筛查。

2025-05-270
OA
Ultrasonic Aspiration-Acquired Glioblastoma Tissue Preserves Lymphocyte Phenotype and Viability, Supporting Its Use for Immunological Studies

超声吸引获取的胶质母细胞瘤组织保留淋巴细胞表型和活性,支持其用于免疫学研究

CANCERS
IF4.4
2025-02-110
OA
Adenovirus-Neutralizing and Infection-Promoting Activities Measured in Serum of Human Brain Cancer Patients Treated with Oncolytic Adenovirus Ad5-△24.RGD

腺病毒中和及感染促进活性在人脑癌患者血清中的测定:该患者接受溶瘤腺病毒Ad5-△24.RGD治疗

2025-01-201
OA
A LOCAL DELIVERY OF HRBMP4 AS AN ANTICANCER THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A FIRST-IN-HUMAN PHASE 1 DOSE ESCALATION TRIAL
2024-10-170
PRE